Literature DB >> 11841524

Use of cholesterol-lowering therapy and related beliefs among middle-aged adults after myocardial infarction.

John Z Ayanian1, Bruce E Landon, Mary Beth Landrum, James R Grana, Barbara J McNeil.   

Abstract

OBJECTIVE: To assess use of cholesterol-lowering therapy and related beliefs among middle-aged adults after myocardial infarction.
DESIGN: Telephone survey and administrative data.
SETTING: National managed-care company. PARTICIPANTS: Six hundred ninety-six adults age 30 to 64 surveyed in 1999, approximately 1 to 2 years after a myocardial infarction. MEASUREMENTS: Use of cholesterol-lowering drugs, beliefs about the importance of lowering cholesterol, and knowledge of personal cholesterol level, adjusting for demographic and clinical factors with logistic regression. MAIN
RESULTS: Among respondents, 62.5% reported they were taking a cholesterol-lowering drug. In adjusted analyses, these drugs were used significantly less often by African-American patients and those with congestive heart failure or peripheral vascular disease, and more often by college graduates, patients with hypertension, and those who had seen a cardiologist since their myocardial infarction. Lowering cholesterol was viewed as "very important"; by 87.1% of patients, but significantly less often by smokers and more often by those who had undergone coronary angioplasty or bypass surgery. Only 42.5% of respondents knew their cholesterol level, and this knowledge was significantly less common among less-educated or less-affluent patients, African-American patients, and patients who smoked or had diabetes or peripheral vascular disease.
CONCLUSIONS: Although most patients recognized the importance of lowering cholesterol after myocardial infarction, several clinical and demographic subgroups were less likely to receive cholesterol-lowering therapy, and many patients were unaware of their cholesterol level. Health-care providers and managed-care plans can use these findings to promote cholesterol testing and treatment for patients with coronary heart disease who are most likely to benefit from these efforts.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11841524      PMCID: PMC1495008          DOI: 10.1046/j.1525-1497.2002.10438.x

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  32 in total

1.  Racial variation in the use of coronary-revascularization procedures. Are the differences real? Do they matter?

Authors:  E D Peterson; L K Shaw; E R DeLong; D B Pryor; R M Califf; D B Mark
Journal:  N Engl J Med       Date:  1997-02-13       Impact factor: 91.245

2.  Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.

Authors:  M Johannesson; B Jönsson; J Kjekshus; A G Olsson; T R Pedersen; H Wedel
Journal:  N Engl J Med       Date:  1997-01-30       Impact factor: 91.245

3.  Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). The HERS Research Group.

Authors:  H G Schrott; V Bittner; E Vittinghoff; D M Herrington; S Hulley
Journal:  JAMA       Date:  1997 Apr 23-30       Impact factor: 56.272

4.  Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals.

Authors:  G Schectman; J Hiatt
Journal:  Am J Med       Date:  1996-02       Impact factor: 4.965

5.  Inadequate treatment with HMG-CoA reductase inhibitors by health care providers.

Authors:  J J Marcelino; K R Feingold
Journal:  Am J Med       Date:  1996-06       Impact factor: 4.965

6.  Variations in cholesterol management practices of U.S. physicians.

Authors:  R S Stafford; D Blumenthal; R C Pasternak
Journal:  J Am Coll Cardiol       Date:  1997-01       Impact factor: 24.094

7.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

8.  Racial differences in the use of revascularization procedures after coronary angiography.

Authors:  J Z Ayanian; I S Udvarhelyi; C A Gatsonis; C L Pashos; A M Epstein
Journal:  JAMA       Date:  1993-05-26       Impact factor: 56.272

9.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

Authors: 
Journal:  N Engl J Med       Date:  1998-11-05       Impact factor: 91.245

10.  The National Cholesterol Education Program: progress and prospects.

Authors:  J I Cleeman; C Lenfant
Journal:  JAMA       Date:  1998 Dec 23-30       Impact factor: 56.272

View more
  9 in total

1.  Challenges in making therapeutic lifestyle changes among hypercholesterolemic African-American patients and their physicians.

Authors:  Rhonda Dailey; Kendra L Schwartz; Juliann Binienda; Jessica Moorman; Anne Victoria Neale
Journal:  J Natl Med Assoc       Date:  2006-12       Impact factor: 1.798

2.  The heart truth professional education campaign on women and heart disease: needs assessment and evaluation results.

Authors:  Janet Pregler; Karen M Freund; Mary Kleinman; Maureen G Phipps; Rose S Fife; Becky Gams; Ana E Núñez; Margaret R Seaver; Cathy J Lazarus; Nancy C Raymond; Joan Briller; Sebastian Uijtdehaage; Cindy S Moskovic; Gretchen Guiton; Michele David; Geralde V Gabeau; Stacie Geller; Kelli Meekma; Christopher Moore; Candace Robertson; Gloria Sarto
Journal:  J Womens Health (Larchmt)       Date:  2009-10       Impact factor: 2.681

Review 3.  Review of evidence and explanations for suboptimal screening and treatment of dyslipidemia in women. A conceptual model.

Authors:  Catherine Kim; Timothy P Hofer; Eve A Kerr
Journal:  J Gen Intern Med       Date:  2003-10       Impact factor: 5.128

4.  Ambulatory hypercholesterolemia management in patients with atherosclerosis. Gender and race differences in processes and outcomes.

Authors:  Stephen D Persell; Saverio M Maviglia; David W Bates; John Z Ayanian
Journal:  J Gen Intern Med       Date:  2005-02       Impact factor: 5.128

5.  National trends in statin use by coronary heart disease risk category.

Authors:  Jun Ma; Niraj L Sehgal; John Z Ayanian; Randall S Stafford
Journal:  PLoS Med       Date:  2005-05-31       Impact factor: 11.069

6.  The gender specific frequency of risk factor and CHD diagnoses prior to incident MI: a community study.

Authors:  Barbara P Yawn; Peter C Wollan; Roy A Yawn; Steven J Jacobsen; Veronique Roger
Journal:  BMC Fam Pract       Date:  2007-04-04       Impact factor: 2.497

7.  Factors associated with lipid goal attainment among acute coronary syndrome patients.

Authors:  Siti-Zainora Mohd-Zulkefli; Marhanis-Salihah Omar; Adyani Md-Redzuan
Journal:  Patient Prefer Adherence       Date:  2016-08-24       Impact factor: 2.711

8.  Disparities in lipid management for African Americans and Caucasians with coronary artery disease: a national cross-sectional study.

Authors:  Mark W Massing; Kathleen A Foley; Lori Carter-Edwards; Carla A Sueta; Charles M Alexander; Ross J Simpson
Journal:  BMC Cardiovasc Disord       Date:  2004-08-18       Impact factor: 2.298

9.  Equity in the use of antithrombotic drugs, beta-blockers and statins among Finnish coronary patients.

Authors:  Kristiina Manderbacka; Ilmo Keskimäki; Antti Reunanen; Timo Klaukka
Journal:  Int J Equity Health       Date:  2008-06-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.